Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of September 9, 2026, MYGN trades at $3.10 with a market cap of $305.12M and a P/E ratio of -2.68. MYGN moved +0.00% today. Year to date, MYGN is -48.29%; over the trailing twelve months it is -53.98%. Its 52-week range spans $2.74 to $15.47. Analyst consensus is sell with an average price target of $2.95. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
7 analysts cover MYGN: 0 strong buy, 0 buy, 4 hold, 3 sell, and 0 strong sell. The consensus rating is sell. The average price target is $2.95.
| Metric | Value |
|---|---|
| Price | $3.10 |
| Market Cap | $305.12M |
| P/E Ratio | -2.68 |
| EPS | $-1.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.47 |
| 52-Week Low | $2.74 |
| Volume | 90.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $806.60M |
| Net Income | $-112.60M |
| Gross Margin | 68.83% |
7 analysts cover MYGN: 0 strong buy, 0 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is sell. Average price target: $2.95.